Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver
tumor-killing substances to them without harming normal cells. Zoledronate may prevent bone
loss and stop the growth of tumor cells in bone. It is not yet known whether monoclonal
antibody is more effective than zoledronate in treating women who have breast cancer and bone
metastases.
PURPOSE: Randomized phase I/II trial to compare the effectiveness of monoclonal antibody with
that of zoledronate in treating women who have breast cancer and bone metastases.